-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] In recent days, the pharmaceutical index has continued to rise, and the industry believes that the next sector index may still have a certain upward spa.
With the strengthening of the pharmaceutical sector, the approval of related ETF products has also accelerated recent.
On July 5th, the first batch of vaccine ETFs and Chinese medicine ETFs in China were approved, including 3 vaccine ETFs and 4 Chinese medicine ET.
Specifically, the three vaccine ETFs approved this time are from three public offerings of Huatai-Pineapple, Cathay Pacific, and Fuguo; the four traditional Chinese medicine ETFs are products of Huatai-Pineapple, Penghua, Yinhua, and China Univers.
It is reported that the indices tracked by the above two batches of ETFs are the China Securities Traditional Chinese Medicine Index and the China Securities Vaccine Biotechnology Ind.
Among them, the Vaccine and Biotechnology Index selects 50 sample stocks in the fields of biological products, biological testing, and biotechnology services, including Zhifei Bio, Watson Bio, and Fosun Phar.
The CSI Traditional Chinese Medicine Index selects 50 sample stocks related to the production and sales of traditional Chinese medicine, including Yiling Pharmaceutical, Zhongsheng Pharmaceutical, Shanghai Kaibao,e.
Affected by the news that these two batches of ETFs have been approved, the Hong Kong stock pharmaceutical ETF has strengthened on JulyAs of the close on the 6th, the Hong Kong stock pharmaceutical ETF and the Hong Kong Stock Connect pharmaceutical ETF rose by more than 3%, and the Hong Kong pharmaceutical ETF follow.
In addition to the accelerated approval of ETFs, many head fund companies are also actively deploying pharmaceutical-themed fun.
For example, in June, Harvest Fund submitted the application materials for the A-share vaccine industry-themed index-based fund on June 2; on June 10, Penghua Fund submitted to the China Securities Regulatory Commission the application materials of its national securities vaccine and biotechnology E.
Application materials, on the same day, China Asset Management reported a China Securities Vaccine and Biotechnology Index Sponsored Fund; on June 17, three companies, Bosera, China Merchants, and Harvest submitted the application materials for the China Securities Vaccine and Biotechnology ETF on the same d.
At present, the above application materials have been received and are awaiting approv.
Funds have accelerated into pharmaceutical stocks, which shows that they are optimistic about the pharmaceutical-related tra.
Among them, in the field of traditional Chinese medicine, in recent years, the state has vigorously supported the development of traditional Chinese medicine, and favorable policies have been continuously introduced and implemented, which has brought development momentum to the traditional Chinese medicine indust.
And the long-term valuation is low, and it is expected to usher in a valuation reshapi.
Traditional Chinese medicine has the attributes of consumer goods and health care produc.
With the aging of the population and the upgrading of residents' consumption, the industry generally predicts that the traditional Chinese medicine industry will have great prospects in the futu.
Southwest Securities also believes that the traditional Chinese medicine sector continues to benefit from the triple positives of “marginal policy + product price increase + state-owned enterprise reform”, and the traditional Chinese medicine sector, especially traditional Chinese medicine consumer goods, and exclusive traditional Chinese medicine essential medicine varieties have relative benefi.
Debon Securities is still optimistic about the vaccine sect.
He believes that the long-term logic of the vaccine industry is still improving: first, the vaccine industry has no policy risks, and it is one of the few policy immunization sub-sectors; second, conventional vaccines will be significantly recovered in 2022, and the main business of vaccine companies will appear in 202 The growth rate of performance will be dazzling; third, the vaccine company has undergone adjustment for nearly half a year, and the current valuation is already in a very cost-effective positi.
In the field of vaccines, with the official promulgation of China's "Vaccine Management Law" in 2019, the supervision of the vaccine industry has become stricter, and the entire industry has entered a new stage of "strict and ne.
With the acceleration of vaccine innovation and research and the advancement of more policy reforms, the continuous influx of capital, and the reshaping of the domestic vaccine industry structure, in this context, local medium and large vaccine companies have been listed to achieve industrial upgrading, or are expected to embrace new opportuniti.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
With the strengthening of the pharmaceutical sector, the approval of related ETF products has also accelerated recent.
On July 5th, the first batch of vaccine ETFs and Chinese medicine ETFs in China were approved, including 3 vaccine ETFs and 4 Chinese medicine ET.
Specifically, the three vaccine ETFs approved this time are from three public offerings of Huatai-Pineapple, Cathay Pacific, and Fuguo; the four traditional Chinese medicine ETFs are products of Huatai-Pineapple, Penghua, Yinhua, and China Univers.
It is reported that the indices tracked by the above two batches of ETFs are the China Securities Traditional Chinese Medicine Index and the China Securities Vaccine Biotechnology Ind.
Among them, the Vaccine and Biotechnology Index selects 50 sample stocks in the fields of biological products, biological testing, and biotechnology services, including Zhifei Bio, Watson Bio, and Fosun Phar.
The CSI Traditional Chinese Medicine Index selects 50 sample stocks related to the production and sales of traditional Chinese medicine, including Yiling Pharmaceutical, Zhongsheng Pharmaceutical, Shanghai Kaibao,e.
Affected by the news that these two batches of ETFs have been approved, the Hong Kong stock pharmaceutical ETF has strengthened on JulyAs of the close on the 6th, the Hong Kong stock pharmaceutical ETF and the Hong Kong Stock Connect pharmaceutical ETF rose by more than 3%, and the Hong Kong pharmaceutical ETF follow.
In addition to the accelerated approval of ETFs, many head fund companies are also actively deploying pharmaceutical-themed fun.
For example, in June, Harvest Fund submitted the application materials for the A-share vaccine industry-themed index-based fund on June 2; on June 10, Penghua Fund submitted to the China Securities Regulatory Commission the application materials of its national securities vaccine and biotechnology E.
Application materials, on the same day, China Asset Management reported a China Securities Vaccine and Biotechnology Index Sponsored Fund; on June 17, three companies, Bosera, China Merchants, and Harvest submitted the application materials for the China Securities Vaccine and Biotechnology ETF on the same d.
At present, the above application materials have been received and are awaiting approv.
Funds have accelerated into pharmaceutical stocks, which shows that they are optimistic about the pharmaceutical-related tra.
Among them, in the field of traditional Chinese medicine, in recent years, the state has vigorously supported the development of traditional Chinese medicine, and favorable policies have been continuously introduced and implemented, which has brought development momentum to the traditional Chinese medicine indust.
And the long-term valuation is low, and it is expected to usher in a valuation reshapi.
Traditional Chinese medicine has the attributes of consumer goods and health care produc.
With the aging of the population and the upgrading of residents' consumption, the industry generally predicts that the traditional Chinese medicine industry will have great prospects in the futu.
Southwest Securities also believes that the traditional Chinese medicine sector continues to benefit from the triple positives of “marginal policy + product price increase + state-owned enterprise reform”, and the traditional Chinese medicine sector, especially traditional Chinese medicine consumer goods, and exclusive traditional Chinese medicine essential medicine varieties have relative benefi.
Debon Securities is still optimistic about the vaccine sect.
He believes that the long-term logic of the vaccine industry is still improving: first, the vaccine industry has no policy risks, and it is one of the few policy immunization sub-sectors; second, conventional vaccines will be significantly recovered in 2022, and the main business of vaccine companies will appear in 202 The growth rate of performance will be dazzling; third, the vaccine company has undergone adjustment for nearly half a year, and the current valuation is already in a very cost-effective positi.
In the field of vaccines, with the official promulgation of China's "Vaccine Management Law" in 2019, the supervision of the vaccine industry has become stricter, and the entire industry has entered a new stage of "strict and ne.
With the acceleration of vaccine innovation and research and the advancement of more policy reforms, the continuous influx of capital, and the reshaping of the domestic vaccine industry structure, in this context, local medium and large vaccine companies have been listed to achieve industrial upgrading, or are expected to embrace new opportuniti.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
